Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities
Date:8/4/2011

andidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unrespectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical development; CSP-9222 and OGX-225 are currently in pre-clinical development.

OncoGenex' Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial initiation and completion dates, patient enrollment targets, proposed amendments to our ongoing clinical trial design and the timing and possibility for approval by the FDA thereof, the timing and costs of our product development activities and the potential benefits of our product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk of delays in our expected clinical trials and the uncertainties regarding patient enrollment rates, the risk that the FDA does not approve our proposed amendment to the Saturn trial design in a timely fashion or at all, the risk that our product candidates do not obtain the requisite regulatory approvals to commercialize, the risk that new developments in the rapidly evolving prostate cancer therapy landscape require additional changes in our clinical trial design or lim
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011
2. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
3. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
4. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
5. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
6. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
7. Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call
8. Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities
9. Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
10. Gamma Pharmaceuticals, Inc. Holds Special Shareholders Meeting
11. Sigma-Tau Pharmaceuticals, Inc. Announces Addition of VP of Finance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... application process, CSA Medical, Inc. ( www.CSAmedical.com ) has ... future plans for its proprietary spray cryotherapy platform on ... will take place from 10:20-10:50 am at the Walter ... CSA Medical is first to harness the power of ...
... EMERYVILLE, Calif., Oct. 7 Onyx Pharmaceuticals, Inc. (Nasdaq: ... teleconference to provide a status update on its New Drug ... webcast of the presentation on our website at: ... 847-585-4405 and using the passcode 28119641. A replay of the ...
Cached Medicine Technology:CSA Medical Selected to Present at AdvaMed 2010: The MedTech Conference 2Onyx Pharmaceuticals Announces Teleconference to Provide Status Update on Carfilzomib 2
(Date:4/23/2014)... 2014 Pregnant immigrants from Sub-Saharan Africa, Latin ... during pregnancy, according to new research from St. ... the British Journal of Obstetrics and Gynaecology ... rates among immigrants and native-born women in six ... Sweden, Spain (Catalonia and Valencia) and the United ...
(Date:4/23/2014)... National Institute of Arthritis and Musculoskeletal and Skin Diseases ... Ross Prize in Molecular Medicine, conferred by the Feinstein ... award will be given on June 9 at the ... scientific presentations by Dr. O,Shea and other prominent researchers. ... , The award, which includes a $50,000 prize from ...
(Date:4/23/2014)... that rats exposed to high-energy particles, simulating conditions astronauts ... lapses in attention and slower reaction times, even when ... , The cognitive impairments which affected a large ... appear to be linked to protein changes in the ... hold true in humans, suggest it may be possible ...
(Date:4/23/2014)... BUFFALO, N.Y. A novel compound that targets an ... host of cocaine addiction behaviors, including relapse behavior, a ... research provides strong evidence that this may be a ... no effective medications exist., The UB research was published ... last week. , In the study, the compound, RO5263397, ...
(Date:4/23/2014)... could help doctors predict which patients might suffer potentially ... The program, which assesses brain scans using pattern recognition ... passport control, has been developed by researchers at Imperial ... the Wellcome Trust, which used the software are published ... Stroke affects over 15 million people each year worldwide. ...
Breaking Medicine News(10 mins):Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3
... of expertise and other factors when ... ... CIGNA Behavioral Health,(CBH) members can now view robust, online ... including license,levels, languages spoken, educational background, areas of specialization,and years ...
... -- Researchers at Mayo Clinic in Jacksonville have discovered how ... proteins in the brain, resulting in a common dementia, ... number of age-related neurological disorders. , In the Sept. ... that absence of a gene known as progranulin leads to ...
... be on,display throughout The Kroger Co.,s (NYSE: KR ... partners with vendors and suppliers to support,National Breast Cancer ... tags can be found on shelves in Kroger,stores across ... support breast cancer awareness in their community. Several of,Kroger,s ...
... Climb to Conquer Cancer will follow four professional U.S., ... Alaska, NEW YORK, Sept. 27 Fred Hutchinson ... expedition to an unclimbed,mountain in the name of cancer ... expedition. The inaugural Climb to Conquer Cancer, performed ...
... QMed, Inc.,(Nasdaq: QMED ) today announced it ... August 31, 2007 revenue of approximately $10.8 million and,$26.6 ... $13 million,respectively. The Company,s cash position as of August ... Jane Murray, president and CEO, said, "During the ...
... Edition Strawberry Jelly Krimpets Will Benefit Online ... for Breast Cancer Support and Information, PHILADELPHIA, Sept. ... philanthropic product offering, the,Tastykake Strawberry Jelly Krimpet. 10% of ... will be donated to breastcancer.org, a,Narberth, Pennsylvania based online ...
Cached Medicine News:Health News:CIGNA Behavioral Health Offers Members Online Provider Profiles 2Health News:Loss of gene leads to protein splicing and buildup of toxic proteins in neurons 2Health News:Kroger 'Pink Tag' Campaign to Raise $2.5 Million for Breast Cancer Awareness in October 2Health News:Fred Hutchinson Cancer Research Center Announces the First-Ever Expedition to an Unclimbed Mountain in the Name of Cancer Research 2Health News:QMed, Inc. Comments on Estimated 3rd Quarter Results & Medical Expense Ratio; Sets 2008 Revenue Guidance for Medicare SNPs at $88-95 Million 2Health News:QMed, Inc. Comments on Estimated 3rd Quarter Results & Medical Expense Ratio; Sets 2008 Revenue Guidance for Medicare SNPs at $88-95 Million 3Health News:Tasty Baking Company Launches New Krimpet to Support Breast Cancer Awareness Through a Partnership with Breastcancer.Org 2Health News:Tasty Baking Company Launches New Krimpet to Support Breast Cancer Awareness Through a Partnership with Breastcancer.Org 3
... The ACS:180 SE is a ... PLUS, consisting of important physical ... simplify routine operation and increase ... the "Next Generation" ACS:180. The ...
... wide range of Platelet aggregometers allows ... meet particular needs. Single, dual and ... chart recorder outputs or digital computer ... Optical aggregometers, which measure platelet aggregation ...
... you in achieving improved cost efficiency ... to cut costs is constantly increasing. ... eliminate unnecessary manual interactions. Ensuring security ... control mechanisms like pipetting integrity check. ...
... Advia 2400 has minimal ... (as low as 2 ... (40 L/hour) thus maximizing ... universal rack handler facilitates ...
Medicine Products: